Document Detail

Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease.
MedLine Citation:
PMID:  18691349     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Adalimumab is an effective treatment in patients with Crohn's disease; as it is a humanized anti-tumour necrosis factor monoclonal antibody, immunogenicity is thought not to be of any significance.
AIM: To assess whether antibodies to adalimumab (ATAs) affect adalimumab treatment outcome in patients with Crohn's disease previously treated with infliximab.
METHODS: A retrospective study was performed. Patients with active Crohn's disease and who had lost response or were intolerant to infliximab were treated with adalimumab. Clinical response and side effects were assessed as were serum ATAs and antibodies to infliximab (ATIs).
RESULTS: In total 30 patients [M/F (7/23)], median age 36 years (range 21-73) were treated with adalimumab for 318 days (median range 83-632). Clinical response was 77% (23/30), a dose escalation was necessary in eight (27%) patients and side effects were observed in 47% (14/30). In five patients (17%) ATAs were detected; of these patients, four were nonresponders. The presence of ATAs was related to nonresponse to adalimumab (P = 0.006). ATIs were positive in 57% of patients (17/30) and serum levels were significantly increased in adalimumab nonresponders (P = 0.01).
CONCLUSION: Immunogenicity plays a role in adalimumab treatment because of the development of ATAs.
R L West; Z Zelinkova; G J Wolbink; E J Kuipers; P C F Stokkers; C J van der Woude
Related Documents :
19288029 - Effect of mdr1 gene promoter methylation in patients with ulcerative colitis.
12131609 - Chronic colitis is associated with a reduction of mucosal alkaline sphingomyelinase act...
17530399 - Prevalence of pancreatic insufficiency in inflammatory bowel diseases. assessment by fe...
17903939 - Cerebral venous sinus thrombosis in a patient with ulcerative colitis.
17890779 - Enhanced atherogenesis and altered high density lipoprotein in patients with crohn's di...
20848459 - Risk factors for metabolic bone disease in crohn's disease patients.
7877749 - Challenging current accounts of unilateral neglect.
21802259 - Features of acute dwi abnormalities related to status epilepticus.
14563449 - Serum markers of monocyte/macrophage activation in patients with alzheimer's disease an...
Publication Detail:
Type:  Journal Article     Date:  2008-08-08
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  28     ISSN:  1365-2036     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-10-30     Completed Date:  2009-02-20     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1122-6     Citation Subset:  IM    
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Inflammatory Agents / administration & dosage*,  immunology
Antibodies, Monoclonal / administration & dosage*,  immunology
Antibodies, Monoclonal, Humanized
Crohn Disease / drug therapy*,  immunology
Dose-Response Relationship, Drug
Middle Aged
Retrospective Studies
Treatment Outcome
Tumor Necrosis Factor-alpha / administration & dosage*,  immunology
Young Adult
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Tumor Necrosis Factor-alpha; 0/infliximab; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Relative torque contribution of vastus medialis muscle at different knee angles.
Next Document:  Hepatitis vaccination in patients with hepatitis C: practice and validation of codes at a large Vete...